In short
This article summarizes clinical trials investigating the use of a pneumococcal vaccine containing serotype 9V polysaccharide conjugated to CRM197 and adsorbed on aluminum phosphate. The vaccine is being studied in various populations including healthy adults, infants, and those at increased risk of pneumococcal disease. The trials aim to evaluate the safety, immunogenicity, and effectiveness of this vaccine formulation against pneumococcal infections.
At a glance
- Populations studied
- Healthy adults, infants, adults ≥60 years, adults 18-64 at increased risk
- Main objectives
- Safety, tolerability, immunogenicity, effectiveness against pneumococcal disease
- Vaccine administration
- Intramuscular injection, single or multiple dose regimens
- Key endpoints
- Antibody responses, disease rates, adverse events, vaccine effectiveness
- Special considerations
- Co-administration with other vaccines, effectiveness in high-risk groups
- Study designs
- Randomized controlled trials, observational studies
- Geographic locations
- Multiple countries involved
What is the pneumococcal polysaccharide serotype 9V conjugate vaccine?
The pneumococcal polysaccharide serotype 9V conjugate vaccine is a component of broader pneumococcal conjugate vaccines like Prevenar 13 and Apexxnar. It contains parts of the outer coating (polysaccharide) of the pneumococcus bacteria serotype 9V, which is chemically linked (conjugated) to a non-toxic variant of diphtheria toxin called CRM197. This conjugate is then adsorbed onto aluminum phosphate to enhance the immune response.
This vaccine is designed to protect against infections caused by the Streptococcus pneumoniae bacteria, specifically the 9V serotype. Streptococcus pneumoniae can cause serious illnesses like pneumonia, meningitis, and bloodstream infections (sepsis).
How does it work?
The vaccine works by stimulating the immune system to produce antibodies against the 9V serotype of pneumococcus. Here's a breakdown of its components:
- Polysaccharide: This is a part of the outer coating of the pneumococcus bacteria. By itself, it doesn't produce a strong, long-lasting immune response, especially in young children.
- CRM197: This is a carrier protein that helps the immune system recognize the polysaccharide better. It enhances the immune response, particularly in infants and young children.
- Aluminum phosphate: This acts as an adjuvant, further boosting the immune response to the vaccine.
When vaccinated, your body recognizes these components as foreign and produces antibodies against them. If you're later exposed to the actual 9V serotype pneumococcus bacteria, your immune system can quickly recognize and fight off the infection.
Who is this vaccine for?
The pneumococcal polysaccharide serotype 9V conjugate vaccine, as part of broader pneumococcal conjugate vaccines, is recommended for:
- Infants and young children
- Adults 65 years and older
- People with certain medical conditions that increase their risk of pneumococcal disease
Specific recommendations may vary by country and individual health status. Always consult with your healthcare provider to determine if this vaccine is appropriate for you or your child.
How is it administered?
The vaccine is typically administered as an intramuscular injection, usually in the thigh for infants or the upper arm for older children and adults. It's given as part of a series of shots, with the number of doses depending on the age at which vaccination begins and individual risk factors.
For example, in the United States, the CDC recommends the following schedule for pneumococcal conjugate vaccines in children:
- 2 months of age
- 4 months of age
- 6 months of age
- 12-15 months of age (booster dose)
For adults, a single dose may be sufficient, but some high-risk individuals may need additional doses. Your healthcare provider will determine the appropriate schedule for you.
Effectiveness
Studies have shown that pneumococcal conjugate vaccines, including the serotype 9V component, are highly effective in preventing invasive pneumococcal disease caused by the included serotypes. For instance, research indicates that these vaccines have reduced invasive pneumococcal disease in children by more than 90% for the included serotypes.
The effectiveness can vary depending on factors such as age, overall health, and specific pneumococcal serotypes. It's important to note that while the vaccine is very effective against the included serotypes, it doesn't protect against all types of pneumococcal bacteria.
Safety and side effects
Pneumococcal conjugate vaccines, including the serotype 9V component, are generally considered safe. Like all vaccines, they can cause side effects, but serious reactions are rare. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Mild fever
- Irritability in infants
- Fatigue
- Headache
- Muscle or joint pain
These side effects are usually mild and resolve on their own within a few days. Severe allergic reactions are very rare but can occur. If you experience symptoms of a severe allergic reaction (such as difficulty breathing, rapid heartbeat, or dizziness) after receiving the vaccine, seek medical attention immediately.
Ongoing research
Research on pneumococcal vaccines is ongoing, with scientists working to improve their effectiveness and broaden protection against more serotypes. For example, clinical trials are being conducted on new formulations that include additional serotypes.
One such study is evaluating the immune response to a 20-valent pneumococcal conjugate vaccine (which includes serotype 9V) in adults aged 65 and older. This research aims to determine the vaccine's effectiveness against vaccine-type radiologically-confirmed community-acquired pneumonia.
These ongoing studies help ensure that pneumococcal vaccines continue to provide optimal protection against pneumococcal diseases as the bacteria evolve and new serotypes emerge.